Hepatitis C: Tackling the silent epidemic

British Journal of Hospital Medicine

Volumn 66, Issue 10, 2005, Pages 579-582

  Hamlyn, Adrian N ^a  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27544432321     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2005.66.10.19897     Document Type: Review

References (20)

1. Bonkovsky HL, Woolley JM (1999) Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 29: 264-70
2. British Liver Trust (2002) Hepatitis C - The Public Stealth Disease. British Liver Trust, Ringwood
3. Choo Q-L, Kuo G, Weiner AJ et al (1989) Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-62
4. Davis GL, Esteban-Mur R, Rustgi V et al (1998) Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339: 1493-9
5. Department of Health (2002) Hepatitis C strategy for England. DoH, London
6. Detre KM, Belle SH, Lombardero M (1997) Liver transplantation for chronic viral hepatitis. Viral Hepat Rev 2: 219-28
7. Di Bisceglie AM (1998) Hepatitis C. Lancet 351: 351-5
8. Grace MJ, Cutler D (2004) Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antivir Chem Chemother 15: 287-97
9. Health Protection Agency (2003) Shooting Up - Infections among injecting drug users in the United Kingdom 2002. An Update: December 2003. Health Protection Agency, London
10. Joint Formulary Committee (2005) British National Formulary. 49th ed. British Medical Association and Royal Pharmaceutical Society of Great Britain, London
11. Mohsen AH, Group TH; Trent HCV Study Group (2001) The epidemiology of hepatitis C in a UK health regional population of 5.12 million. Gut 48: 707-13
12. Myers RP, Regimbeau C, Thevenot T et al (2002) Interferon for interferon naive patients with chronic hepatitis C (Cochrane Review). Cochrane Database Syst Rev CD000370
13. National Institute for Clinical Excellence (2004) Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. Technical Appraisal Guidance 75. National Institute for Clinical Excellence, London
14. Neary MP, Cort S, Bayliss MS, Ware JE Jr (1999) Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 19(Suppl 1): 77-85
15. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825-32
16. Poynard T, McHutchison J, Goodman Z, et al (2000) Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 31: 211-18
17. Poynard T, Yuen MF, Ratziu V, Lai CL (2003) Viral hepatitis C. Lancet 362: 2095-100
18. Shepherd J, Brodin H, Cave C et al (2003) Pegylated interferon alpha 2a and 2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review. Wessex Institute for Health Research and Development. University of Southampton, Southampton
19. Thomas HC, Weatherall DT, Ledingham J, Warrell DA (1996) Clinical features of viral hepatitis. In: Thomas HC, Weatherall DT, Ledingham J, Warrell DA, eds. Oxford Textbook of Medicine. 3rd edn. Oxford University Press, Oxford: 2061-9
20. WHO (1997) Hepatitis C: Global Update. Wkly Epidemiol Rec 72: 341-4